Blogs

Category

Behind the Breakthrough: Q&A with Lyn Baranowski, Avalyn Pharma

Lyn Baranowski, CEO of Avalyn Pharma, brings more than two decades of experience serving in a range of diverse leadership positions across biotech, big pharma, and venture capital firms with a focus on the respiratory therapeutic area.

As Baranowski reflects on her career path, she notes that working in this space is the “common thread” connecting her professional experiences. Lyn began her tenure in the field at Novartis, where she first learned of less known lung diseases like pulmonary fibrosis and pulmonary hypertension.

Behind the Breakthrough: Q&A with Peptone, Kamil Tamiola

Kamil Tamiola’s approach to better understand disease-causing proteins reflects his passion to study protein disorders.

Intrinsically disordered proteins (dubbed IDPs) and intrinsically disordered regions (IDRs) occur in one-third of the human proteome. Disordered proteins are shape-shifting and lack a consistent 3D structure. As a result, IDPs cannot be visualized using existing experimental methods, such as microscopy and mass spectrometry, or by predictive modeling approaches. Determined to “see” the invisible in the disordered proteome, Tamiola and his team have used interdisciplinary collaboration to address this longstanding challenge.

New Digital Care Architecture: The “Four Ds of Digital Health” Meet the “Two As of Automation”

Building on the "Four Ds of Digital Health", two key automation advancements are being incorporated to make an impact: artificial intelligence and API-based services.

A new digital care architecture is transforming healthcare by integrating the Three Ds of healthcare delivery (doctors, drugs, and diagnostics) with data, AI, and API-based services, creating a more accessible, personalized, and efficient system for both patients and providers.

Pioneering Progress: The FARAPULSE™ Story

With atrial fibrillation (AF) on the rise, Farapulse’s pulsed field ablation (PFA) approach is transforming treatment options by offering a safer, more precise alternative to traditional methods, with potential applications beyond AF.

F-Prime is dedicated to advancing pioneering science and technologies that redefine patient care and treatment. Since 2002, F-Prime has facilitated the regulatory approval and commercialization of 33 products and drugs. In our new series, Pioneering Progress, we will be showcasing success stories behind the approval of drugs and products from our portfolio companies.

Pioneering Progress: The Lenmeldy™ Story

Orchard Therapeutics’ Lenmeldy™ is a first of its kind treatment for an ultra-rare pediatric hereditary disorder.

F-Prime is dedicated to advancing pioneering science and technologies that redefine patient care. Since 2002, F-Prime has facilitated the regulatory approval and commercialization of 33 products and drugs. In our series, Pioneering Progress, we will be showcasing the success stories behind the approval of drugs and products from our portfolio companies.